News | November 04, 2024
Briefs: Sun Pharmaceutical Industries and Biocon Biologics
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
The partnership emphasises the introduction of renewable, bio-based materials into existing plastic applications to help reduce fossil resource dependency
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
The company reported a net profit of Rs 46.15 crore in Q2 FY25 as compared to Rs 23.88 crore in Q2 FY24
Extension of long-term collaboration includes construction of new customer-dedicated bioconjugation capacity in Visp (CH) and commercial antibody supply of a new ADC
Revolf's infertility and miscarriage tests are a new technology that uses blood tests to detect neoself-antibodies
Product basket comprises 2,047 medicines and 300 surgical devices covering all major therapeutic groups
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Efficacy and safety from this phase IV study were consistent with data from the Vabysmo phase III DME studies
Enhertu demonstrated clinically meaningful efficacy in previously treated patients
Subscribe To Our Newsletter & Stay Updated
